Erratum: Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41 (Journal of Medicinal Chemistry (2011) 54 (7220-7231) 10.1021/jm200791z);Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41

Journal of Medicinal Chemistry

Volumn 54, Issue 20, 2011, Pages 7220-7231

  Zhou, Guangyan ^a   Wu, Dong ^a   Snyder, Beth ^b   Ptak, Roger G ^b   Kaur, Harmeet ^a   Gochin, Miriam ^a,c  

^a Touro University California   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 METHOXYPHENYL)METHYL 6 BROMOINDOLE; 2,6 DICHLORO QUINOLINE; 3 (1H INDOL 6 YLMETHYL) 4 NITRO BENZOIC ACID; 3 (1H INDOL 6 YLMETHYL) 5 METHOXY BENZOIC ACID; 3 (1H INDOL 6 YLMETHYL)BENZOIC ACID; 3 HYDROXY 5 (1H INDOL 6 YLMETHYL)BENZOIC ACID; 3 [(1 (3 METHOXYPHENYL) 1H INDOL 6 YL)METHYL]BENZOIC ACID; 3 [(1H INDOL 5 YL)METHYL]BENZOIC ACID; 3 [(3 FORMYL 1H INDOL 6 YL)METHYL]BENZOIC ACID; 3 [6 (3 CARBOXYBENZYL) 1H INDOL 1 YL]BENZOIC ACID; 3 [[1 (3 CARBOXYBENZYL) 1H INDOL 5 YL]METHYL]BENZOIC ACID; 3 [[1 (3 CARBOXYBENZYL) 1H INDOL 6 YL]METHYL]BENZOIC ACID; 3 [[1 (4 METHOXYBENZYL) 1H INDOL 6 YL]METHYL]BENZOIC ACID; 3 [[3 (CARBOXYCARBONYL) 1H INDOL 6 YL]METHYL] BENZOIC ACID; 3 [[3 [1 (3 CARBOXYBENZYL) 1H INDOL 6 YL]PHENOXY]METHYL]BENZOIC ACID; 3 [[3 [[6 [3 (4 METHOXYBENZYLOXY)PHENYL] 1H INDOL 1 YL]METHYL]BENZOYLOXY]METHYL]BENZOIC ACID; 3 [[6 (3 HYDROXYPHENYL) 1H INDOL 1 YL]METHYL]BENZOIC ACID; 3 [[6 (3 METHOXYPHENYL) 1H INDOL 1 YL]METHYL]BENZOIC ACID; 3 [[6 (6 CHLORO 2 QUINOLY)INDOL 1 YL]METHYL]BENZOIC ACID; 3,3' (1,1' METHYLENEBIS(1H INDOLE 6,1 DIYL))BIS(METHYLENE)DIBENZOIC ACID; 4 (1H INDOL 6 YLMETHYL) 5 METHOXY BENZOIC ACID; 4 HYDROXY 3 (1H INDOL 6 YLMETHYL)BENZOIC ACID; 5 (6 CHLORO 2 QUINOLYL)INDOLE; 6 (3 HYDROXYPHENYL) 1H INDOLE; 6 (6 CHLORO 2 QUINOLYL)INDOLE; 6 [1 [(4 METHOXYPHENYL)METHYL]INDOL 6 YL]INDOLE; 6 [3 [ (4 METHOXYPHENYL)METHOXY]PHENYL] 1H INDOLE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; METHYL 3 (1H INDOL 6 YLMETHYL)BENZOATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; VIRUS REPLICATION;

EID: 80054910151     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201545q     Document Type: Erratum

References (45)

1. Caffrey, M.; Cai, M.; Kaufman, J.; Stahl, S. J.; Wingfield, P. T.; Covell, D. G.; Gronenborn, A. M.; Clore, G. M. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41 EMBO J. 1998, 17, 4572-4584 (Pubitemid 28377158)
2. Chan, D. C.; Fass, D.; Berger, J. M.; Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein Cell 1997, 89, 263-273 (Pubitemid 27199898)
3. Gallo, S. A.; Puri, A.; Blumenthal, R. HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process Biochemistry (Moscow) 2001, 40, 12231-12236 (Pubitemid 32959744)
4. Matthews, T.; Salgo, M.; Greenberg, M.; Chung, J.; DeMasi, R.; Bolognesi, D. Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes Nat. Rev. Drug Discovery 2004, 3, 215-225 (Pubitemid 38379988)
5. Welch, B. D.; VanDemark, A. P.; Heroux, A.; Hill, C. P.; Kay, M. S. Potent D-peptide inhibitors of HIV-1 entry Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 16828-16833 (Pubitemid 350210950)
6. Eckert, D. M.; Malashkevich, V. N.; Hong, L. H.; Carr, P. A.; Kim, P. S. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket Cell 1999, 99, 103-115 (Pubitemid 29468634)
7. Welch, B. D.; Francis, J. N.; Redman, J. S.; Paul, S.; Weinstock, M. T.; Reeves, J. D.; Lie, Y. S.; Whitby, F. G.; Eckert, D. M.; Hill, C. P.; Root, M. J.; Kay, M. S. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance J. Virol. 2010, 84, 11235-11244
8. Chan, D. C.; Chutkowski, C. T.; Kim, P. S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15613-15617 (Pubitemid 29018748)
9. Liu, S.; Wu, S.; Jiang, S. HIV entry inhibitors targeting gp41: From polypeptides to small-molecule compounds Curr. Pharm. Des. 2007, 13, 143-162 (Pubitemid 46085289)
10. Ernst, J. T.; Kutzki, O.; Debnath, A. K.; Jiang, S.; Lu, H.; Hamilton, A. D. Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion Angew. Chem., Int. Ed. Engl. 2002, 41, 278-281 (Pubitemid 34118069)
11. Jiang, S.; Lu, H.; Liu, S.; Zhao, Q.; He, Y.; Debnath, A. K. N-Substituted Pyrrole Derivatives as Novel Human Immunodeficiency Virus Type 1 Entry Inhibitors Antimicrob. Agents Chemother. 2004, 48, 4349-4359
12. Teixeira, C.; Barbault, F.; Rebehmed, J.; Liu, K.; Xie, L.; Lu, H.; Jiang, S.; Fan, B.; Maurel, F. Molecular modeling studies of N-substituted pyrrole derivatives-Potential HIV-1 gp41 inhibitors Bioorg. Med. Chem. 2008, 16, 3039-3048 (Pubitemid 351418201)
13. Liu, K.; Lu, H.; Hou, L.; Qi, Z.; Teixeira, C.; Barbault, F.; Fan, B. T.; Liu, S.; Jiang, S.; Xie, L. Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41 J. Med. Chem. 2008, 51, 7843-7854
14. Wang, Y.; Lu, H.; Zhu, Q.; Jiang, S.; Liao, Y. Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41 Bioorg. Med. Chem. Lett. 2010, 20, 189-192
15. Katritzky, A. R.; Tala, S. R.; Lu, H.; Vakulenko, A. V.; Chen, Q. Y.; Sivapackiam, J.; Pandya, K.; Jiang, S.; Debnath, A. K. Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3- phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors J. Med. Chem. 2009, 52, 7631-7639
16. Jiang, S.; Tala, S. R.; Lu, H.; Abo-Dya, N. E.; Avan, I.; Gyanda, K.; Lu, L.; Katritzky, A. R.; Debnath, A. K. Design, Synthesis, and Biological Activity of Novel 5-((Arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3- (trifluoromethyl)phe nyl)thiazolidin-4-ones as HIV-1 Fusion Inhibitors Targeting gp41 J. Med. Chem. 2011, 54, 572-579
17. Frey, G.; Rits-Volloch, S.; Zhang, X. Q.; Schooley, R. T.; Chen, B.; Harrison, S. C. Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 13938-13943 (Pubitemid 44452961)
18. Xu, Y.; Lu, H.; Kennedy, J. P.; Yan, X.; McAllister, L. A.; Yamamoto, N.; Moss, J. A.; Boldt, G. E.; Jiang, S.; Janda, K. D. Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation J. Comb. Chem. 2006, 8, 531-539 (Pubitemid 44116116)
19. Stewart, K. D.; Huth, J. R.; Ng, T. I.; McDaniel, K.; Hutchinson, R. N.; Stoll, V. S.; Mendoza, R. R.; Matayoshi, E. D.; Carrick, R.; Mo, H.; Severin, J.; Walter, K.; Richardson, P. L.; Barrett, L. W.; Meadows, R.; Anderson, S.; Kohlbrenner, W.; Maring, C.; Kempf, D. J.; Molla, A.; Olejniczak, E. T. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket Bioorg. Med. Chem. Lett. 2010, 20, 612-617
20. Balogh, E.; Wu, D.; Zhou, G.; Gochin, M. NMR Second Site Screening for Structure Determination of Ligands Bound in the Hydrophobic Pocket of HIV-1 gp41 J. Am. Chem. Soc. 2009, 131, 2821-2823
21. Gochin, M.; Zhou, G.; Phillips, A. H. Paramagnetic relaxation assisted docking of a small indole compound in the HIV-1 gp41 hydrophobic pocket ACS Chem. Biol. 2010, 6, 267-274
22. Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 2007, 450, 1001-1009 (Pubitemid 350273630)
23. Zhou, G.; Wu, D.; Hermel, E.; Balogh, E.; Gochin, M. Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting Gp41 Bioorg. Med. Chem. Lett. 2010, 20, 1500-1503
24. Cai, L.; Gochin, M. A Novel Fluorescence Intensity Screening Assay Identifies New Low Molecular Weight Inhibitors of the gp41 Coiled Coil Domain of HIV-1 Antimicrob. Agents Chemother. 2007, 51, 2388-2395 (Pubitemid 47047315)
25. Wexler-Cohen, Y.; Shai, Y. Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition FASEB J. 2007, 21, 3677-3684 (Pubitemid 350075155)
26. Kagiampakis, I.; Gharibi, A.; Mankowski, M. K.; Snyder, B. A.; Ptak, R. G.; Alatas, K.; LiWang, P. J. Potent strategy to inhibit HIV-1 by binding both gp120 and gp41 Antimicrob. Agents Chemother. 2011, 55, 264-275
27. Lackman-Smith, C.; Osterling, C.; Luckenbaugh, K.; Mankowski, M.; Snyder, B.; Lewis, G.; Paull, J.; Profy, A.; Ptak, R. G.; Buckheit, R. W., Jr.; Watson, K. M.; Cummins, J. E., Jr.; Sanders-Beer, B. E. Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides Antimicrob. Agents Chemother. 2008, 52, 1768-1781 (Pubitemid 351614671)
28. Curry, S. Lessons from the crystallographic analysis of small molecule binding to human serum albumin Drug Metab. Pharmacokinet. 2009, 24, 342-357
29. Wendt, M. D. Discovery of ABT-263, a Bcl-family protein inhibitor: Observations on targeting a large protein-protein interaction Expert Opin. Drug Discovery 2008, 3, 1123-1143
30. Jiang, S.; Debnath, A. K. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity Biochem. Biophys. Res. Commun. 2000, 270, 153-157 (Pubitemid 30440408)
31. Welch, B. D.; VanDemark, A. P.; Heroux, A.; Hill, C. P.; Kay, M. S. Potent D-peptide inhibitors of HIV-1 entry Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 16828-16833 (Pubitemid 350210950)
32. Gochin, M.; Zhou, G. Amphipathic properties of HIV-1 gp41 fusion inhibitors. Curr. Top. Med. Chem. 2011, in press.
33. Lin, J.; Sahakian, D. C.; de Morais, S. M.; Xu, J. J.; Polzer, R. J.; Winter, S. M. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery Curr. Top. Med. Chem. 2003, 3, 1125-1154
34. Hajduk, P. J.; Mendoza, R.; Petros, A. M.; Huth, J. R.; Bures, M.; Fesik, S. W.; Martin, Y. C. Ligand binding to domain-3 of human serum albumin: a chemometric analysis J. Comput.-Aided Mol. Des. 2003, 17, 93-102 (Pubitemid 37062773)
35. Miyaura, N.; Suzuki, A. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds Chem. Rev. 1995, 95, 2457-2483
36. Fanta, P. E. The Ullmann Synthesis of Biaryls Synthesis 1974, 1974, 9-21
37. Djerassi, C. Brominations with N-bromosuccinimide and related compounds; the Wohl-Ziegler reaction Chem. Rev. 1948, 43, 271-317
38. Platt, E. J.; Wehrly, K.; Kuhmann, S. E.; Chesebro, B.; Kabat, D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1 J. Virol. 1998, 72, 2855-2864 (Pubitemid 28175522)
39. Wei, X.; Decker, J. M.; Liu, H.; Zhang, Z.; Arani, R. B.; Kilby, J. M.; Saag, M. S.; Wu, X.; Shaw, G. M.; Kappes, J. C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy Antimicrob. Agents Chemother. 2002, 46, 1896-1905 (Pubitemid 34535213)
40. Ciminale, V.; Felber, B. K.; Campbell, M.; Pavlakis, G. N. A bioassay for HIV-1 based on Env-CD4 interaction AIDS Res. Hum. Retroviruses 1990, 6, 1281-1287
41. Popovic, M.; Read-Connole, E.; Gallo, R. C. T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III Lancet 1984, 2, 1472-1473 (Pubitemid 15175156)
42. Popovic, M. S.; Gartner, E.; Read-Connole, B.; Beaver, M.; Reitz, M. Cell tropism and expression of HIV-1 isolated in natural targets. In Retroviruses of Human AIDS and Related Animal Diseases; Valette, L.; Girard, M., Eds.; Pasteur Vaccins: Marnes-La-Coquette, France, 1989; pp 219-224.
43. Ratner, L.; Haseltine, W.; Patarca, R.; Livak, K. J.; Starcich, B.; Josephs, S. F.; Doran, E. R.; Rafalski, J. A.; Whitehorn, E. A.; Baumeister, K. Complete nucleotide sequence of the AIDS virus, HTLV-III Nature 1985, 313, 277-284 (Pubitemid 15151982)
44. Chackerian, B.; Long, E. M.; Luciw, P. A.; Overbaugh, J. Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection J. Virol. 1997, 71, 3932-3939 (Pubitemid 27172408)
45. Morris, G. M.; Huey, R.; Olson, A. J. Using AutoDock for ligand-receptor docking. Curr. Protoc. Bioinformatics 2008, Unit 8.14.